Chronic Leukemia News

• CLL: Venetoclax Combos Top First-Line Chemoimmunotherapy A combination of venetoclax, ibrutinib, and obinutuzumab outperforms first-line chemoimmunotherapy for chronic lymphocytic leukemia in otherwise fit adults with few comorbidities.
  MDedge News, May 15, 2023
• CLL: Black Patients Die Sooner Than White Patients Although Black patients are much less likely to develop chronic lymphocytic leukemia than are White patients, they are more likely to die sooner from the disease.
  MDedge News, May 11, 2023
• Frontline CLL Therapy: Avoiding Adverse Events Second-generation Bruton's tyrosine kinase inhibitors are a great frontline option for most, if not all, patients with chronic lymphocytic leukemia (CLL), owing to their improved toxicity profiles.
  MDedge News, April 25, 2023
• Relapsed CLL: New Approaches Prolong Survival Experts discuss treatment options for patients with relapsed chronic lymphocytic leukemia.
  MDedge News, April 20, 2023
• Ibrutinib Price Tag Keeps Rising, Despite Increased Competition Despite increased competition from drugs with better clinical profiles and, in some cases, also lower cost, the price tag and rate of prescribing for ibrutinib continues to increase.
  Medscape Medical News, April 11, 2023
• MRD: Powerful Metric for CLL Research The latest drugs for chronic lymphocytic leukemia (CLL) offer prolonged remission, along with a need for better tools to gauge their effectiveness: measurable residual disease (MRD) could be useful.
  MDedge News, April 07, 2023
• B-Cell Cancers: Sparse Insight Into Preventing Infections "We simply don't know" which preventive strategy is most effective, says expert. Patients will survive their cancers and "be at risk of infection or have significant cytopenias," she warned.
  MDedge News, April 06, 2023
• CLL Treatment: More Infections Among Real-World Patients A high rate of severe infections was seen in patients with chronic lymphocytic leukemia (CLL) or B-cell lymphoma who were taking ibrutinib (Imbruvica), idelalisib (Zydelig), or venetoclax (Venclexta).
  MDedge News, March 09, 2023
• Venetoclax Shows Promise for R/R Hairy Cell Leukemia Five of six patients with relapsed or refractory hairy cell leukemia experienced a response to venetoclax alone or in combination with rituximab.
  Medscape Medical News, March 09, 2023
• Leukemia: Preventing Chemotherapy-Induced Vascular Toxicity Tyrosine kinase inhibitors markedly improve patients' chances of survival but also cause a rise in blood pressure that must be treated quickly.
  Medscape Medical News, February 21, 2023
• Alert FDA OKs Zanubrutinib (Brukinsa) for CLL or SLL The FDA granted accelerated approval to the BTK inhibitor zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
  Medscape Medical News, January 20, 2023
• AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market The company is planning to remove its leukemia drug moxetumomab pasudotox-tdfk (Lumoxiti) from the US market, saying there has been 'very low clinical uptake' of the product.
  Medscape Medical News, January 13, 2023
• New Trials in Leukemia and Lymphoma: Could Your Patient Benefit? Could one of your patients benefit from the latest clinical trials enrolling patients with leukemia or lymphoma?
  Medscape Medical News, January 09, 2023
• CLL Phase 3 Study: Zanubrutinib Bests Ibrutinib The second-generation Bruton's tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .
  MDedge News, December 19, 2022
• ASH 2022 Poorly Matched Stem Cell Transplants Linked to Ancestry Non-European ancestry is a risk factor for receiving the 'most complex' bone marrow transplantations, and this factor is related to socioeconomic status, new results suggest.
  MDedge News, December 10, 2022
• High Cost and Demand for Old Cancer Drug Sparks Crisis As severe shortages of fludarabine drag on and prices soar, transplant centers are struggling to cope. The drug is an essential component of stem-cell transplants for some blood cancers.
  MDedge News, December 06, 2022
• FDA Panel Finds Duvelisib Risks Outweigh Benefits in CLL/SLL An expert panel questioned the value of the FDA-approved drug following 5-year follow-up data that showed a possible increased risk of death among patients with relapsed or refractory CLL/SLL.
  Medscape Medical News, September 26, 2022
• Pivotal Trials in Blood Cancers Don’t Mirror Patient Populations Clinical trials leading to drug approvals for various blood cancers have significantly underrepresented Blacks and minorities, leading to questions about the generalizability of safety and efficacy, say experts.
  Medscape Medical News, September 02, 2022
• Alert Ibrutinib Now Approved for Children With Chronic GVHD Ibrutinib is now approved for chronic graft-vs-host disease in children aged 1 to 12 years and is available in a new oral suspension formulation.
  FDA Approvals, August 25, 2022
• FDA Okays Tablet Version of Acalabrutinib for All Indications The new formulation can be taken with proton pump inhibitors and other gastric acid reducers.
  FDA Approvals, August 05, 2022